

Cancer Treatment Results from Tubercin reported by ArTec, Inc.

Monday November 15, 5:54 pm ET

RENO, Nev.--(BUSINESS WIRE)--Nov. 15, 2004--ArTec, Inc., (Pink Sheets: ATKJ - News) announced that Dr. Tai Ho Chung, formulator of Tubercin and the Company's scientific advisor, along with members of a research team from Kyungpook National University Hospital, Daegu, South Korea, recently reported the successful results on the long term treatment of a 26 year old breast cancer patient. Although already in an advanced stage of the disease, the subject after a treatment protocol that combined Tubercin with conventional radiation has been in remission for the past three years through November 2004. Treatment with Tubercin commenced in the year 2000, primarily because the patient had not responded well to conventional therapies. Three years after the initial treatment, remarkably, the patient remains in remission.

Dr. Chung noted that, "This particular case demonstrates clinically that Tubercin is effective, as an adjuvant to radiation, and can be successfully combined with conventional cancer treatments without the fear of adverse side-effects." He further commented, "There are other cases where Tubercin has been successful with breast cancer as well as other cancers when administered as the only treatment."

Forward-looking statements in this press release, the company cautions the investors, involve risks and uncertainties pursuant to the "Safe Harbor" provisions of the Private Securities Litigation Reform Act of 1995. In addition, the company cautions investors that it undertakes no obligations or responsibilities to publicly update these forward-looking statements to reflect Company's expectations with regard to these forward-looking statements or the occurrence of unanticipated events.